bro there are a few studies on line that suggest the validity of site specific growth from hgh and slin. or try it for yourself and see.
Regulation and action of insulin-like growth factors at the cellular level
L S Phillips, J B Harp, S Goldstein, C I Pao
Proceedings of the Nutrition Society , 49(3):451-458 1990
Present understanding of IGF-1 as a growth factor mediating integration of nutritional-hormonal interactions indicates that IGF-1 acts in both an endocrine mode on distant targets and an autocrine-paracrine mode on local targets. In the liver, the combined presence of GH, insulin, and critical metabolic fuels such as essential amino acids results in increased levels of IGF-1 messenger RNA, increased production of a high-MW IGF-1 precursor, and increased release of IGF-1 into the circulation, permitting action on distant target tissues bearing specific receptors for IGF-1. The net effect is distant amplification of anabolic hormone action via IGF-1 acting in an endocrine mode.
In extrahepatic tissues, both 'general' anabolic hormones (insulin and GH) as well as 'specific' hormones (e.g. gonadotropins) acting on a wide variety of targets (including fibroblasts and chondrocytes as well as granulosa and Leydig cells) promote both local secretion of IGF-1 and an increase in IGF-1 receptors. Local actions of IGF-1 then result in a secondary increase in both hormone receptors and hormone responses. The net effect is local amplification of hormone action via IGF-1 acting as a growth factor in an autocrine-paracrine mode.
Other References:
1. Hertoghe T. Growth hormone therapy in ageing adults 4th Annual meeting of the American Academy of anti-aging Medicine, Las Vegas December 1996.
2. Bouillanne O, Rainfray M, Tissandier O et al. Growth hormone in elderly people: an age-delaying drug? Fundan Clin Pharmacol 1996 10 (5) 416-30.
3. Merimee TJ. Growth hormone secretion and action. Endocrinology DeGroot et al (eds) New York, NY 1979.
4. Thoren M, Hilding M, Baxter RR et al. Serum insulin like growth factor 1(IGF1), IGF binding protein -1 and -3 and the acid labile subunit as serum markers of body composition during growth hormone therapy in adults with GH deficiency. J Clin Endorinol Metabol 1997; 82 (1): 223-8.
5. Johansson JO , Landin K, Johannsson G et al. Long term treatment with growth hormone decreases plasminogen acitivator and tissue plasminogen activator in growth hormone deficient adults. Thromb Haemost 1996; 76 (3): 422-8.
6. Boonen S, Lesaffre E, Aerssens J. Deficiency of the growth hormone insulin like growth factor 1 axis potentially involved in age related abnormalities in body composition. Gerontology 1996; 42 (6): 330-8.
7. Bengt-Ake Bengtsson. Effects of Growth Hormone Deficiency 4th Annual meeting of the American Academy of anti-aging Medicine, Las Vegas December 1996.
8. Jansen YJ, Frolich M, Roelfsema F. A low starting dose of genotropin in growth hormone deficient adults. J Clin Endocrinol Metab 1997; 82 (1): 129-35.
9. Terry CL. Human growth hormone replacement therapy in adults 4th Annual meeting of the American Academy of anti-aging Medicine, Las Vegas December 1996.
10. Klatz R, MD Grow Young with HGH Harper Collins New York, NY 1997.
11. Smith R. A new receptor involved in the control of growth hormone secretion 4th annual meeting American academy of anti-aging medicine Las Vegas 1996.
.gif "IP Gear")
